어스카(ERAS) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

ERAS

Erasca Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$18.87

-0.24 ▼ -1.26%

🌙 7월 27일 5:10 PM ET (한국 7/28 06:10)

$19.33

+0.46 ▲ +2.43%

어스카(ERAS) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$6.6B

스몰캡

P/E

배당수익률

없음

52주 위치

76%

저점 +1319% · 고점 -22%

애널리스트

적극 매수

C+

Fundamental health

vs. 방어주 중형주· based on 2 axes

수익성

산출 불가 (적자)

성장

Top 53%

밸류에이션

데이터 부족

재무 안정

Top 39%

Index ⓘ	RUT	P/E ⓘ	-	EPS (ttm) ⓘ	-0.93	Insider Own ⓘ	39.85%	Shs Outstand ⓘ	310.8M	Perf Week ⓘ	0.27%
Market Cap ⓘ	6.55B	Forward P/E ⓘ	-	EPS next Y ⓘ	41.58%	Insider Trans ⓘ	-0.07%	Shs Float ⓘ	208.8M	Perf Month ⓘ	26.22%
Enterprise Value ⓘ	6.35B	PEG ⓘ	-	EPS next Q ⓘ	-0.11	Inst Own ⓘ	56.89%	Short Float ⓘ	14.74%	Perf Quarter ⓘ	-12.19%
Income ⓘ	-0.28B	P/S ⓘ	-	EPS this Y ⓘ	-114.89%	Inst Trans ⓘ	21.43%	Short Ratio ⓘ	4.64	Perf Half Y ⓘ	89.46%
Sales ⓘ	0.00B	P/B ⓘ	14.9	EPS next 5Y ⓘ	-15.19%	ROA ⓘ	-59.42%	Short Interest ⓘ	30.77M	Perf YTD ⓘ	407.26%
Book/sh ⓘ	1.27	P/C ⓘ	26.87	EPS past 3/5Y ⓘ	39.56% 12.46%	ROE ⓘ	-69.86%	52W High ⓘ	-22.28% ($24.28)	Perf Year ⓘ	984.48%
Cash/sh ⓘ	0.7	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	-	ROIC ⓘ	-63.8%	52W Low ⓘ	1318.69% ($1.33)	Perf 3Y ⓘ	660.89%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	-49.51%	Gross Margin ⓘ	-	Volatility(W/M) ⓘ	4.99% 7.27%	Perf 5Y ⓘ	-0.47%
Dividend TTM ⓘ	-	EV/Sales ⓘ	-	Sales Y/Y TTM ⓘ	-	Oper. Margin ⓘ	-	ATR (14) ⓘ	1.24	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	9.52	EPS Q/Q ⓘ	-451.51%	Profit Margin ⓘ	-	RSI (14) ⓘ	56.47	Recom ⓘ	1.36
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	9.52	Sales Q/Q ⓘ	-	SMA20 ⓘ	-0.34% ($18.93)	Beta ⓘ	0.66	Target Price ⓘ	$22.55
Payout ⓘ	-	Debt/Eq ⓘ	0.12	Earnings ⓘ	2026/5/11	SMA50 ⓘ	22.87% ($15.36)	Rel Volume ⓘ	0.53	Prev Close ⓘ	$19.11
Employees ⓘ	103	LT Debt/Eq ⓘ	0.1	EPS/Sales Surpr. ⓘ	-475.26% -	SMA200 ⓘ	78.17% ($10.59)	Avg Volume(3M) ⓘ	6.64M	Price ⓘ	$18.87
IPO ⓘ	2021/7/16	Option/Short ⓘ	Yes/Yes			Trades ⓘ	19335	Volume ⓘ	3,531,214	Change ⓘ	-1.26%

Quarterly earnings trend SEC filings · USD

23.9

24.3

24.6

24.9

25.3

25.6

25.9

26.3

Revenue Net income 최근 분기: 매출 - · 순이익 $-183M (YoY -492%)

📊 Erasca Inc (ERAS) Investment Analysis

What kind of company is Erasca Inc?

어스카(ERAS) 방어주

Healthcare · Biotechnology

#1213 by Market Cap — Mid-Cap

A clinical-stage biotech company developing oncology drugs. It is developing anti-cancer candidates that target the RAS signaling pathway, which drives cancer, and is conducting clinical trials across a range of solid tumor indications. The company is a biotech firm specialized in RAS-targeted anti-cancer drugs.

Learn more about Erasca Inc →

Market Cap

$6.6B

Approx. KRW 9.0 trillion

⚖️ 2% of Samsung Electronics

Market Cap Rank1213

Employees103people

IPO2021/07/16

Current Price$18.87 ≈ 25,852원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 11일 (월) · 장 마감 후 EPS -475.3%

🔔 Earnings release 2026년 3월 12일 (목) · 장 마감 후 EPS +6.5%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-69.9%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-59.4%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-63.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.12

✓ Healthy debt

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

9.52

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

9.52

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$22.55

현재가 대비 +19.5%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

+41.6%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

-15.2%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

-80.0%

평균 서프라이즈

2026.05.11

하회

실적 $-0.60 · 예상 $-0.23 -166.0%

2026.03.12

상회

실적 $-0.10 · 예상 $-0.11 +6.0%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Expected to Slow

Historical growth is expected to lose momentum

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-114.9%

매우 부진

My positionBottom 5%

Low range Average High range

방어주 중형주 Median 5.2% · Bottom tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+41.6%

우수

My positionTop 25%

Low range Average High range

방어주 중형주 Median 10.7% · Top 22%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

-15.2%

매우 부진

My positionBottom 5%

Low range Average High range

방어주 중형주 Median 7.2% · Bottom tier

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+39.6%

우수

My positionTop 5%

Low range Average High range

방어주 중형주 Median 4.5% · Top 2%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+12.5%

양호

My positionMid-range

Low range Average High range

방어주 중형주 Median 6.5% · Top 41%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -69%p below the market

ERAS -0.5% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-68.8%p

Significantly behind the market

vs Health Care (XLV)

-25.0%p

behind the sector average

1-year basis

vs S&P 500

+968.5%p

well ahead of the market

vs Health Care (XLV)

+964.8%p

well ahead of the sector average

Rank among peers

5-year return Lower-Mid (lower 31%) Based on 64 peers

1-year return Top among peers Based on 76 peers

Current position within 52-week range

Low (-1318.7%p) High (-22.3%p)

Current price is 1318.7% above the 52-week low and 22.3% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-59.5%

Annualized volatility

124.5%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 137-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $18.87 below the midline ($18.93). Normal downward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-27

Neutral zone — weak trend

MACD 1.040 · Signal 1.248 · Hist -0.207. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-27

Bullish zone

RSI 56.5 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 31.2.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry

Pricey on Vs. Assets

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Pricey

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

14.90x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology 중형주 median 6.81x · Bottom 21% — expensive within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

Analyst target price (reference)

$22.55 vs. current price +19.5%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 중형주

Who owns it?

Ownership is broadly stable

Insider modest net selling -0.1% · Institutional net buying +21.4% · Short interest elevated 14.7%

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-0.1%

Insiders little change

🏦 Institutions (funds & investors)

+21.4%

Institutions large net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 56.9%

Adequate institutional weight

Healthcare 중형주 Median 89.4%

🧑‍💼 Insiders 39.9%

Founder/management large holders (strong skin-in-the-game)

Healthcare 중형주 Median 9.4%

👤 Retail investors (estimated) 3.3%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

14.7%

Somewhat high

Healthcare 중형주 Median 11.3%

Past 90 days Little change

Short interest days to cover

4.6 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 310.8M주

Float (tradable shares) 208.8M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding ERAS

ETFs with the highest weightings · 10 total shown

BBC

Virtus Biotech Clinical Trials ETF

2.19%

$47M

PTH

Invesco Dorsey Wright Healthcare Momentum ETF

State Street SPDR S&P Biotech ETF

1.03%

$10.0B

IWC

iShares Micro-Cap ETF

0.64%

$1.4B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
ERAS This Stock	$6.6B	-	14.9 ▼	-69.86% ▼	-	-1.3%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 어스카(ERAS)?

어스카(ERAS) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of ERAS?

The market cap of ERAS is approximately $6.6B, ranking 1,213 within its sector.

What is the 52-week high and low for ERAS?

ERAS has recorded a 52-week high of $24.28 and a low of $1.33.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.